BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
142.75 EUR
-1.6 (-1.11%)
IDP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 86 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making IDP a very profitable company, without any liquidiy or solvency issues. IDP is cheap, but on the other hand it scores bad on growth. These ratings would make IDP suitable for value investing!
1. Profitability
1.1 Basic Checks
- IDP had positive earnings in the past year.
- IDP had a positive operating cash flow in the past year.
- In the past 5 years IDP has always been profitable.
- Each year in the past 5 years IDP had a positive operating cash flow.
1.2 Ratios
- IDP's Return On Assets of 5.51% is amongst the best of the industry. IDP outperforms 81.93% of its industry peers.
- IDP has a Return On Equity of 8.84%. This is amongst the best in the industry. IDP outperforms 81.93% of its industry peers.
- IDP has a better Return On Invested Capital (9.70%) than 85.54% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for IDP is in line with the industry average of 11.58%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
- IDP has a better Profit Margin (15.98%) than 83.13% of its industry peers.
- In the last couple of years the Profit Margin of IDP has declined.
- Looking at the Operating Margin, with a value of 28.50%, IDP belongs to the top of the industry, outperforming 86.75% of the companies in the same industry.
- IDP's Operating Margin has declined in the last couple of years.
- IDP's Gross Margin of 75.24% is fine compared to the rest of the industry. IDP outperforms 66.27% of its industry peers.
- IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
- IDP has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for IDP has been reduced compared to 5 years ago.
- The debt/assets ratio for IDP has been reduced compared to a year ago.
2.2 Solvency
- IDP has an Altman-Z score of 3.22. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.22, IDP is in the better half of the industry, outperforming 71.08% of the companies in the same industry.
- IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
- The Debt to FCF ratio of IDP (2.78) is better than 83.13% of its industry peers.
- A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
- IDP's Debt to Equity ratio of 0.35 is in line compared to the rest of the industry. IDP outperforms 56.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.22 |
ROIC/WACC1.17
WACC8.29%
2.3 Liquidity
- A Current Ratio of 2.72 indicates that IDP has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 2.72, IDP is in line with its industry, outperforming 56.63% of the companies in the same industry.
- A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
- IDP has a Quick ratio of 2.04. This is comparable to the rest of the industry: IDP outperforms 46.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 2.51% over the past year.
- IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.31% yearly.
- The Revenue has been growing slightly by 4.77% in the past year.
- Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
- IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.59% yearly.
- IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.63% yearly.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue Next Year1.93%
Revenue Next 2Y-1.65%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 9.91, the valuation of IDP can be described as reasonable.
- 95.18% of the companies in the same industry are more expensive than IDP, based on the Price/Earnings ratio.
- IDP is valuated cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 10.73 indicates a reasonable valuation of IDP.
- Based on the Price/Forward Earnings ratio, IDP is valued cheaply inside the industry as 97.59% of the companies are valued more expensively.
- IDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.29, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.91 | ||
| Fwd PE | 10.73 |
4.2 Price Multiples
- IDP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IDP is cheaper than 92.77% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, IDP is valued cheaper than 96.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.75 | ||
| EV/EBITDA | 7.31 |
4.3 Compensation for Growth
- The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
- IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (1/16/2026, 7:00:00 PM)
142.75
-1.6 (-1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-06 2026-02-06/amc
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap20.94B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target163.18 (14.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)4.97%
PT rev (3m)10.15%
EPS NQ rev (1m)0.42%
EPS NQ rev (3m)-54.28%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)-0.09%
Revenue NQ rev (3m)-2.47%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)1.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.91 | ||
| Fwd PE | 10.73 | ||
| P/S | 2.42 | ||
| P/FCF | 10.75 | ||
| P/OCF | 9.91 | ||
| P/B | 1.34 | ||
| P/tB | 10.2 | ||
| EV/EBITDA | 7.31 |
EPS(TTM)14.41
EY10.09%
EPS(NY)13.31
Fwd EY9.32%
FCF(TTM)13.28
FCFY9.3%
OCF(TTM)14.4
OCFY10.09%
SpS59.06
BVpS106.84
TBVpS13.99
PEG (NY)N/A
PEG (5Y)N/A
Graham Number186.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.22 |
F-Score5
WACC8.29%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.93%
Revenue Next 2Y-1.65%
Revenue Next 3Y-1.2%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.